Pharmaceutical and medical technology cluster Pharmopolis

Transcription

1 Pharmaceutical and medical technology cluster Pharmopolis

2 Pharmopolis Mission Innovative medical city Pharmopolis creates a unique environment for the development of Your business in Russia Pharmopolis residents: Large pharmaceutical and medical technology companies (the core companies of the cluster) Pharmopolis key strengths: Ideal location and logistics Strong government support Medium companies engaged in pharmaceutical and medical technology production, including companies providing services to core companies Joint ventures of Russian and foreign pharmaceutical and medical device companies Professional cluster management team The most favorable conditions for foreign companies willing to establish manufacturing units in Russia Access to high-skilled and experienced workforce living in Moscow and Moscow region 50% of residents to be foreign companies

3 State policy in the field of medical and pharmaceutical industries National Security Strategy of Russian Federation until 2020 Course aimed at pharmaceutical products import substitution Pharmaceutical industry development strategy in RF (Pharma-2020) Domestic product share increase within domestic market by the year 2020 from 20% up to 50%. Concept of RF Health Development until 2020 In billion USD is allocated from the federal budget for purchasing of 100 thousand items of medical equipment Concept of RF Medical Industry development until 2020 Increasing share of domestic medical equipment production by 2020 from 12% till 40% Conclusion: stimulation of international companies to create manufacturing capacity on the territory of Russian Federation => creation of pharmaceutical cluster on the territory of Russian Federation

4 State support of domestic manufacturers Federal target program Development of The Pharmaceutical and Medical Technology Industry of The Russian Federation for the period till 2020 and beyond Financial foundation for development of pharmaceutical and medical technology industries in Russia (EUR 4.5 billion in ) List of strategically important pharmaceutical products to be manufactured in Russia Includes 57 pharmaceutical products, manufacturing of which should be organized in Russia until Foreign manufacturers potential losses 0.7 billion USD Joint Decree of Ministry of Industry and Trade and Ministry of Economic Development Manufacturers on the territory of RF are released from the limitations of participation in tenders (up to 15% from the margin) Conclusion: stimulation of international companies to create manufacturing capacity on the territory of Russian Federation => creation of pharmaceutical cluster on the territory of Russian Federation

5 Pharmopolis as a state initiative Initiators of the project: State Corporation Russian Technologies The Government of the Moscow region Volokolamsk municipal district Administration Agreement 47-РТ/ dd On cooperation for realization of project Pharmopolis Full support of the project by the federal government, regional and local authorities Managing company of the project: OOO «MedPharmTechnologia» Highly qualified management team with experience in launching Sanofi-Aventis Vostok plant (insulin production) in Orel city, Russia Services provided to cluster residents: support with plant construction and infrastructure, drug and medical device registration, clinical studies, legal support, marketing, distribution, headhunting.

6 Ideal location and logistics Indicator Moscow Moscow region Population, mln. people 10,6 6,8 Per capita income per month, $ Investments in fixed capital, billion. $ 21 11,5 Map of the Moscow region Budget expenditure for public health service in 2010, billion. $ 3,72 0,72 Pharmopolis Pharmopolis location: 98 km to Moscow 3 km to Volokolamsk 500 km to the state border with Latvia (EU) 130 km to Sheremetyevo International Airport (passenger and cargo) Customs station in Volokolamsk (one of the 4 customs stations in the Moscow region) Volokolamsk district is actively developing. Largest investment projects under way: - Moscow Raceway - the first and only Formula 1 circuit in Russia (to be opened in July, 2012); - industrial park Volokolamsky ; - business aviation airport 6 branches of Moscow universities in Volokolamsk (possibility to open special training programs) Population of Volokolamsk district is 53 thousand people, of which 24,3 thousand live in Volololamsk city

7 Land plot and infrastructure Location: Volokolamsk district, Moscow region Area : 206 ha The project to be realized in 3 stages: 1 st 61 ha (core companies sites); 2 nd 119 ha (facilities of medium and servicing companies); 3 rd 26 ha (joint ventures) Category: land for industrial use Right of use type: rent with right of renewal High degree of construction site readiness Infrastructure, communications and connection points: Located along the main road of regional significance «Volokolamsk-Zhdanovo» Transforming sub stations are located within 500 m distance, ( ) Gas distribution station is located within 700 m distance, ( )

8 Functional classification of project zones (for the 1 st stage of the project) The exhibition unit will host an ongoing trade fair of medical devices and pharmaceutical products manufactured by cluster residents

9 Key technical and economic indicators for the 1st stage of the project Type of area Area, ha % of total area Land plot area Area of production and laboratory unit 36,6 60 Area of logistics unit 6,1 10 Area of power unit and engineering constructions 3,05 5 Area of research unit 1,22 2 Area of social unit (including offices and exhibition center) 3,05 5 Area of hard-surface roads 1,83 3 Area of paved walkways 1,22 2 Parking space area 1,83 3 Gardening area 6,1 10 Land plot area 61 ha Gross construction area 21 ha Total area of buildings sq. m Electric power supply required power of 32 MW Water consumption 25 cubic meters per hour Wastewater disposal 15 cubic meters per hour Heating supply 4,5 gigacalories per hour Gas supply cubic meters per hour Overall project cost totals EUR 405* million, of which: - Utilities EUR 37 million, incl.: - Technological connections: EUR 12 million; - Out of site communications: EUR 25 million; - Major unit of construction EUR 191 million; - Equipment EUR 156 million; - Other EUR 21 million. * The calculations do not include cost of land acquisition.

10 Investments in Functional Zones Functional Zone Objects Located within Functional Zone Object area, sq. m Investments, EUR * incl. construction, excl. land acquisition Cost of construction Manufacturing unit Manufacturing units of 7 large enterprises Common manufacturing unit for 10 companies Administrative unit Research unit Administrative building, incl. exhibition center ( sq. m) Research unit with pilot production Logistic unit Logistic terminal ** Energy Sector The cogeneration power station may be installed to reduce the cost of electricity and heating supply TOTAL (without cogeneration power station) ** (with cogeneration power station)

11 Technical and economic indicators: the case of Sanofi Aventis manufacturing unit Land plot area 4 ha Gross construction area 1 ha Total area of buildings sq. m Electric power supply required power 4 MW Water consumption 2,5 cubic meters per hour Wastewater disposal 1,25 cubic meters per hour Heating supply 0,5 gigacalories per hour Gas supply cubic meters per hour (in case of own boiler house construction), 30 cubic meters per hour for production needs

12 Efficiency of government support measures for the cluster resident s operating unit Joint Decree of Ministry of Industry and Trade and Ministry of Economic Development Manufacturers on the territory of RF are released from the limitations of participation in tenders (15% margin) Additional gross income of cluster resident will equal EUR 1.5 million for every EUR 10 million On preferential tax treatment in the Moscow region Income tax rate reduction by 4 p.p. (16% instead of 20%) In case of annual gross income of EUR 2 million, the annual benefits will amount to EUR 80,000 50% corporate property tax rate reduction (1,1% instead of 2,2%) In case of capital expenditures of EUR 35 million, the annual benefits will amount to EUR 385,000 In case of EUR 10 million annual revenue and EUR 2 million annual gross income the amount of additional net income for 3 years of operation will equal EUR 5 million (14% of project s investment costs)

13 Support measures applied when Pharmopolis receives Special Economic Zone status 2013 and beyond Favorable business environment in Pharmopolis Special Economic Zone Special Tax Treatment: Reduction in contributions to social security rate from 30% to 14%. In case of EUR 1 million annual salary budget, savings will amount to EUR 0.16 million Income tax rate decrease by 4.5 p.p. (from 20% to 15.5%). In case of EUR 2 million annual gross income, the annual savings will amount to EUR Property tax exemption. In case of EUR 35 million capital expenditures, annual savings will equal EUR 0.77 million Free customs area treatment: No import duty and VAT on imported goods (raw materials, components). In case of EUR 1 million annual imports, annual savings will constitute up to EUR 0.2 million

14 Efficiency of government support measures at the investment stage 2012 Measures to support investment projects implemented in Russia 50% reduction in project documentation costs 50% reduction in the cost of technological connection to the power network Providing the necessary engineering infrastructure area (100% financing from state budget) If the project costs EUR 40 million - reduction in investment costs of EUR 4 million. 10% of the investment cost of the project 2013 Support measures in special economic zone in the cluster Pharmopolis 50% reduction in project documentation costs Free technological connection to the power networks Provision of land plot with necessary engineering, transport, social, customs infrastructure (100% from the budget) exemption from customs duties and VAT on foreign goods imported into Special Economic Zone (cost savings of up to 20%) If the project costs EUR 40 million- reduction in investment costs up to EUR 9 million. 22% of the investment cost of the project

15 Sales volume, billion. USD Overview of Russian pharmaceutical market 7,2% 20,0 15,0 10,0 5,0 0,0 12,6 9,0 Source: «Pharmexpert» 7,3% 11,7% Russian Pharmaceutical market dynamics, , billion USD 16,3 15,7 11,6 11,8 17,7 13,3 2,0 3,0 2,6 2,9 1,6 1,7 1,3 1, Hospital purchases Retail sales 12,6% Beneficiary supplies The structure of Russian pharmaceutical market within the context of drug groups 4,5% 7,2% A: Alimentary tract and metabolism- 19,7% N: Nervous system drugs- 12,8% 4,3% 19,7% C: Cardiovascular system drugs-12,6% R: Respiratory system drugs- 11,7% 5,6% M: Musculoskeletal system drugs- 7,3% 6,9% 12,8% G: Genitourinary system drugs and sex hormones- 7,2% Total J: Antibacterials for systemic use- 6,9% D: Dermatological- 5,6% L: Antineoplastic and immunomodulating agent- 4,3% [~] Without allocation- 4,5% V: Various- 7,2%

16 Overview of Russian medical device market Medical device market in RF in , million USD Indicator 2009 % 2010 % Local production , ,1 Import , ,9 Market volume Data sources: Rosstat, Federal Customs Service The structure of Russian medical device market Basic hospital equipment; 5% Laboratory diagnostics; 6% Dialysis equipment; 5% Surgery and intensive care; 18% X-rays; 12% Other; 5% Diagnostic imaging; 49% The volume of the Russian market for medical equipment is expected to grow from 3.5 billion USD in 2010 to 16 billion USD in 2020 (357% growth) as per the forecast of Ministry for industry and trade of the Russian Federation. More than 50% of the equipment in Russian hospitals is older than 10 years. The market is heavily dependent on imports. Public tender make up 95% of the Russian market for medical equipment (2010: 3.7 billion USD; Federal Ministry of Industry and Trade).

17 Contacts «MedPharmTechnologia» Dokuchaev Sergey Tel.: +7(495) Yurgel Nickolay Tel.: +7(495) Pisarevskaya Irina Tel.: +7(495) Mob.: +7(915)